HUGEL, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 210,500 KRW | +4.47% |
|
+4.47% | +40.90% |
| May. 16 | Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on February 13, 2024. | CI |
| Mar. 27 | Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares. | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 370B 272M | Sales 2025 * | 434B 318M | Capitalization | 2,186B 1.6B |
|---|---|---|---|---|---|
| Net income 2024 * | 102B 74.77M | Net income 2025 * | 133B 97.49M | EV / Sales 2024 * | 4.71 x |
| Net cash position 2024 * | 442B 324M | Net cash position 2025 * | 520B 381M | EV / Sales 2025 * | 3.84 x |
| P/E ratio 2024 * |
24.7
x | P/E ratio 2025 * |
18.4
x | Employees | 562 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 45.67% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.47% | ||
| 1 week | +4.47% | ||
| Current month | -0.47% | ||
| 1 month | +3.95% | ||
| 3 months | +16.04% | ||
| 6 months | +40.52% | ||
| Current year | +40.90% |
1 week
196 600.00
213 500.00
1 month
195 800.00231 000.00
Current year
147 100.00231 000.00
1 year
99 700.00231 000.00
3 years
99 700.00279 500.00
5 years
99 332.34279 500.00
10 years
55 499.45279 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sun-Ho Han
COO | Chief Operating Officer | 59 | 17-12-31 |
Dong-Hoon Oh
CTO | Chief Tech/Sci/R&D Officer | 52 | 14-06-30 |
Chang-Jin Lee
CTO | Chief Tech/Sci/R&D Officer | 52 | 13-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Suk-Yong Cha
CHM | Chairman | 70 | 23-03-29 |
| 50 | - | ||
Han-Soo Keyoung
BRD | Director/Board Member | 50 | 22-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.39% | 2 M€ | -14.14% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +5.31% | - | |
| 0.00% | 34 M€ | +4.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 210,500 | +4.47% | 59,610 |
| 24-05-17 | 201,500 | +1.77% | 66,606 |
| 24-05-16 | 198,000 | -0.50% | 43,659 |
| 24-05-14 | 199,000 | -1.24% | 40,300 |
End-of-day quote Korea S.E., May 19, 2024
More quotes
Hugel Inc is a Korea-based company mainly engaged in the manufacture of biopharmaceuticals. The Company's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The Company sells its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
210,500
KRW
Average target price
224,889
KRW
Spread / Average Target
+6.84%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +40.90% | 1.61B | |
| -3.30% | 89.69B | |
| +3.95% | 41.34B | |
| -10.51% | 33.72B | |
| +60.58% | 26.11B | |
| -20.09% | 14.63B | |
| -8.92% | 12.84B | |
| -11.46% | 11.66B | |
| -43.05% | 11.52B | |
| +5.17% | 8.92B |
- Stock Market
- Equities
- A145020 Stock